Macroaxis: Personalized Investing
Personalized Investing and
Digital Wealth Optimization

GILD AMGN BIIB CELG Processed Foods Real Estate Music and Video 
Benchmark  United States  NYSE  10,930   6.91 Index Moved Down -0.06%  


Processing
Collecting data for STEM

StemCells Inc

   
$1.72
Change0.021.18%
Year To Date
1.152.43
Last 1 Month(s)
1.652.34
Trading Day 
1.661.72
5 Days Price Trend
July 30, 2014 
Highest Price  
Lowest Price  
July 3, 2014 
July 28, 2014 

StemCells Market Sensitivity

As market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, StemCells will likely underperform.
StemCells Inc Large BetaStemCells Inc Beta Legend
STEM
StemCells Inc
USA Stock
Healthcare
Biotechnology
Benchmark NYSE
http://www.stemcellsinc.com
Contact Number: 510. 456. 4000
Currency: USD - US Dollar
Traded on Nasdaq Capital Markets
 
Current Valuation104.41 M
Shares Outstanding55.51 M
Number of Shares Shorted1.81 M
Revenue1.26 M
 thisGreen STEM STEM agains markets  1.18 % Macroaxis: change 1.18 Moved Up  
 
 United States Nasdaq   0.45 % Macroaxis: 0.45 Moved Up  
 
 United States Russel   0.43 % Macroaxis: 0.43 Moved Up  
 
 United States SP 500   0.01 % Macroaxis: 0.01 Moved Up  
 
 United States NYSE   0.06 % Macroaxis: 0.06 Moved Down  
 
Compare to Competition   Compare Correlations

StemCells Leadership

Martin McGlynn CEO and President Director, Member of Strategic Transactions Committee, CEO of StemCells California Inc and President of StemCells California Inc
John Schwartz Independent Chairman of the Board, Ph.D
Gregory Schiffman CFO, Executive Vice President - Finance, MBA
CPA MBA CFO and Executive VP of Fin.

StemCells Diversification Suggestion

Use StemCells to enhance returns of your portfolios. The stock experiences large bullish trend. Check odds of StemCells to be traded at $1.892 in 30 days

StemCells Price and Market Media

The median price of StemCells for the period between Mon, Jun 30, 2014 and Wed, Jul 30, 2014 is 1.68 with a coefficient of variation of 64.11. The daily time series for the period is distributed with a sample standard deviation of 1.19, arithmetic mean of 1.86, and mean deviation of 0.65. The Stock received some media coverage during the period.
StemCells Value
 
Change Benchmark  Embed  Timeline 

StemCells Summary

StemCells Inc [STEM] is traded on Nasdaq Capital Markets in USA. It is located in Newark, CA and employs 58 people. The company currently falls under 'Small-Cap' category with current market capitalization of 111.03 M. StemCells Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 55.51 M outstanding shares of which 1.81 M shares are at this time shorted by private and institutional investors with about 3.5 trading days to cover.
StemCells, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies for stem cellbased research and drug discovery and development. more
Past Market
Over 30
Days
0
Out Of
100
 
Chance of
More
Than
93
%
 
Hyped down

StemCells Alerts

StemCells Inc generates negative expected return over the last 30 days
StemCells Inc may become a speculative penny stock
StemCells Inc has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 1.26 M. Net Loss for the year was (27.64 M) with profit before overhead, payroll, taxes, and interest of 886.64 K.
STEMCELLS INC currently holds about 26.46 M in cash with (23.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48.

StemCells Research Report

  
Generate Report  

StemCells Pair Trading Analysis

Correlation analysis and pair trading evaluation for StemCells and Gilead Sciences
  

StemCells Executives

CPA MBA CFO and Executive VP of Fin.

StemCells Directors

Eric Bjerkholt Independent Director
R Greer Independent Director
Irving Weissman Director
Ricardo Levy Independent Director
Megan Meloni Director of Investor Relations and Corporate Communications

StemCells Management

George Koshy Chief Accounting Officer and Controller
Kenneth Stratton General Counsel

StemCells Fundamentals

StemCells vs Competition

StemCells vs. Gilead Sciences Inc
StemCells vs. Amgen Inc
StemCells vs. Biogen Idec Inc
StemCells vs. Celgene Corporation
StemCells vs. Alexion Pharmaceuticals Inc
StemCells vs. Regeneron Pharmaceuticals Inc
StemCells vs. Illumina Inc
StemCells vs. Vertex Pharmaceuticals Incorporated
StemCells vs. Incyte Corporation
StemCells vs. BioMarin Pharmaceutical Inc

StemCells July 30, 2014 Opportunity Range


 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities